These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 20384603

  • 1. Ranibizumab treatment in patients with neovascular age-related macular degeneration and very low vision.
    Sørensen TL, Kemp H.
    Acta Ophthalmol; 2011 Feb; 89(1):e97. PubMed ID: 20384603
    [No Abstract] [Full Text] [Related]

  • 2. Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study.
    Sadda SR, Stoller G, Boyer DS, Blodi BA, Shapiro H, Ianchulev T.
    Retina; 2010 Oct; 30(9):1390-9. PubMed ID: 20924261
    [Abstract] [Full Text] [Related]

  • 3. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Arias L, Ruiz-Moreno JM, Gómez-Ulla F, Fernández M, Montero J.
    Retina; 2009 Oct; 29(10):1444-9. PubMed ID: 19730163
    [Abstract] [Full Text] [Related]

  • 4. Ranibizumab treatment for neovascular age-related macular degeneration in patients with good baseline visual acuity (better than 6/12): 12-month outcomes.
    Raja MS, Saldana M, Goldsmith C, Burton BJ.
    Br J Ophthalmol; 2010 Nov; 94(11):1543-5. PubMed ID: 20516142
    [No Abstract] [Full Text] [Related]

  • 5. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
    Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR, MARINA Study Group.
    Ophthalmology; 2007 Feb; 114(2):246-52. PubMed ID: 17270674
    [Abstract] [Full Text] [Related]

  • 6. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
    Cohen SY, Dubois L, Tadayoni R, Fajnkuchen F, Nghiem-Buffet S, Delahaye-Mazza C, Guiberteau B, Quentel G.
    Am J Ophthalmol; 2009 Sep; 148(3):409-13. PubMed ID: 19477713
    [Abstract] [Full Text] [Related]

  • 7. Re: development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ziemssen F, Heiduschka P, Schraermeyer U, Tübingen Bevacizumab Study Group.
    Retina; 2007 Oct; 27(8):1154-6; author reply 1156-8. PubMed ID: 18040264
    [No Abstract] [Full Text] [Related]

  • 8. Early clinical experience with ranibizumab for occult and minimally classic neovascular membranes in age-related macular degeneration.
    Mantel I, Zografos L, Ambresin A.
    Ophthalmologica; 2008 Oct; 222(5):321-3. PubMed ID: 18617755
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy.
    Kumar A, Sahni JN, Stangos AN, Campa C, Harding SP.
    Br J Ophthalmol; 2011 Apr; 95(4):530-3. PubMed ID: 20937739
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
    Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK.
    Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
    [Abstract] [Full Text] [Related]

  • 11. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study.
    Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW, Esquiabro M.
    Am J Ophthalmol; 2009 Jul; 148(1):43-58.e1. PubMed ID: 19376495
    [Abstract] [Full Text] [Related]

  • 12. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.
    Boyer DS, Heier JS, Brown DM, Francom SF, Ianchulev T, Rubio RG.
    Ophthalmology; 2009 Sep; 116(9):1731-9. PubMed ID: 19643495
    [Abstract] [Full Text] [Related]

  • 13. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ferrara N, Damico L, Shams N, Lowman H, Kim R.
    Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab.
    Barbazetto I, Saroj N, Shapiro H, Wong P, Freund KB.
    Retina; 2010 Oct; 30(9):1376-85. PubMed ID: 20683380
    [Abstract] [Full Text] [Related]

  • 16. Time course of morphologic effects on different retinal compartments after ranibizumab therapy in age-related macular degeneration.
    Ahlers C, Golbaz I, Stock G, Fous A, Kolar S, Pruente C, Schmidt-Erfurth U.
    Ophthalmology; 2008 Aug; 115(8):e39-46. PubMed ID: 18675694
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab.
    Funk M, Karl D, Georgopoulos M, Benesch T, Sacu S, Polak K, Zlabinger GJ, Schmidt-Erfurth U.
    Ophthalmology; 2009 Dec; 116(12):2393-9. PubMed ID: 19815292
    [Abstract] [Full Text] [Related]

  • 19. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
    Kaiser PK, Blodi BA, Shapiro H, Acharya NR, MARINA Study Group.
    Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
    [Abstract] [Full Text] [Related]

  • 20. Effect of ranibizumab retreatment frequency on neurosensory retinal volume in neovascular amd.
    Keane PA, Chang KT, Liakopoulos S, Jivrajka RV, Walsh AC, Sadda SR.
    Retina; 2009 May; 29(5):592-600. PubMed ID: 19289984
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.